Eli Lilly and Company (LLY)vsFirst Tracks Biotherapeutics (TRAX)
LLY
Eli Lilly and Company
$1,137.76
+2.02%
HEALTHCARE · Cap: $994.92B
TRAX
First Tracks Biotherapeutics
$36.44
-4.05%
HEALTHCARE · Cap: $1.41B
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 33.5% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
TRAX
Avoid23
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.9x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : TRAX
The strongest argument for TRAX centers on Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : TRAX
The primary concerns for TRAX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while TRAX is a value play — different risk/reward profiles.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 23/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →First Tracks Biotherapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
First Tracks Biotherapeutics (Ticker: TRAX) is a forward-thinking biotechnology company focused on developing targeted therapeutics for chronic diseases, utilizing advanced research methodologies and proprietary technologies. The firm is committed to addressing significant unmet medical needs by prioritizing both the safety and efficacy of its innovative drug candidates. As TRAX progresses through clinical trials, it is actively pursuing strategic partnerships to enhance its development pipeline and expand its market footprint, reflecting its dedication to improving patient outcomes within the biopharmaceutical sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?